These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26173300)

  • 1. Using Prescription Drug Monitoring Programs to Address Drug Abuse.
    Hansen M
    NCSL Legisbrief; 2015 Mar; 23(12):1-2. PubMed ID: 26173300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drug monitoring and dispensing of prescription opioids.
    Brady JE; Wunsch H; DiMaggio C; Lang BH; Giglio J; Li G
    Public Health Rep; 2014; 129(2):139-47. PubMed ID: 24587548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research.
    Worley J
    Issues Ment Health Nurs; 2012 May; 33(5):319-28. PubMed ID: 22545639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use.
    Rutkow L; Chang HY; Daubresse M; Webster DW; Stuart EA; Alexander GC
    JAMA Intern Med; 2015 Oct; 175(10):1642-9. PubMed ID: 26280092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disclosure of Use and Abuse of Controlled Substances Among Psychiatric Outpatients.
    De Marco Centeno P; Baig M; Lee SE; Lane CJ; Lagomasino IT
    J Psychiatr Pract; 2015 Nov; 21(6):412-8. PubMed ID: 26554323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combating an Epidemic of Prescription Opioid Abuse.
    Pon D; Awuah K; Curi D; Okyere E; Stern CS
    J Calif Dent Assoc; 2015 Nov; 43(11):673-8. PubMed ID: 26798885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Minnesota Prescription Monitoring Program.
    Herman C
    Northwest Dent; 2011; 90(2):33-5. PubMed ID: 21667591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New DEA rules expand options for controlled substance disposal.
    Peterson DM
    J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):22-6. PubMed ID: 25607591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions.
    Deyo RA; Irvine JM; Millet LM; Beran T; O'Kane N; Wright DA; McCarty D
    Health Aff (Millwood); 2013 Mar; 32(3):603-13. PubMed ID: 23406570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug diversion administrative revocation and application hearings for medical and pharmacy practitioners: a primer for navigating murky, drug-infested waters.
    Mulrooney JJ; Hull AJ
    Albany Law Rev; 2014-2015; 78(2):101-64. PubMed ID: 25330551
    [No Abstract]   [Full Text] [Related]  

  • 11. Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse.
    Grecu AM; Dave DM; Saffer H
    J Policy Anal Manage; 2019; 38(1):181-209. PubMed ID: 30572414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prescription drug monitoring programs in the United States of America].
    El Burai Félix S; Mack K
    Rev Panam Salud Publica; 2014 Oct; 36(4):270-6. PubMed ID: 25563153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions.
    Bao Y; Wen K; Johnson P; Jeng PJ; Meisel ZF; Schackman BR
    Health Aff (Millwood); 2018 Oct; 37(10):1596-1604. PubMed ID: 30273045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug monitoring programs: examining limitations and future approaches.
    Griggs CA; Weiner SG; Feldman JA
    West J Emerg Med; 2015 Jan; 16(1):67-70. PubMed ID: 25671011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain.
    Fishman SM; Papazian JS; Gonzalez S; Riches PS; Gilson A
    Pain Med; 2004 Sep; 5(3):309-24. PubMed ID: 15367312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disclosure to participate in State Prescription Drug Monitoring Programs. Interim final rule.
    Department of Veterans Affairs
    Fed Regist; 2013 Feb; 78(28):9589-93. PubMed ID: 23476981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of state prescription drug monitoring programs: a state-by-state survey.
    Manasco AT; Griggs C; Leeds R; Langlois BK; Breaud AH; Mitchell PM; Weiner SG
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):847-51. PubMed ID: 27061342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative analysis of prescribers' and dispensers' views on improving prescription drug monitoring programs.
    Carnes NA; Wright ER; Norwood CW
    Res Social Adm Pharm; 2017 Nov; 13(6):1167-1174. PubMed ID: 28007411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do prescription monitoring programs impact state trends in opioid abuse/misuse?
    Reifler LM; Droz D; Bailey JE; Schnoll SH; Fant R; Dart RC; Bucher Bartelson B
    Pain Med; 2012 Mar; 13(3):434-42. PubMed ID: 22299725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combating the prescription painkiller epidemic: a national prescription drug reporting program.
    Shepherd J
    Am J Law Med; 2014; 40(1):85-112. PubMed ID: 24844043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.